0001104659-22-088650.txt : 20220810 0001104659-22-088650.hdr.sgml : 20220810 20220810163049 ACCESSION NUMBER: 0001104659-22-088650 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 EFFECTIVENESS DATE: 20220810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvectis Pharma, Inc. CENTRAL INDEX KEY: 0001875558 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 862405608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-455560 FILM NUMBER: 221152219 BUSINESS ADDRESS: STREET 1: 1 BRIDGE PLAZA, SUITE 275 CITY: FORT LEE STATE: NJ ZIP: 07024 BUSINESS PHONE: 360-837-7232 MAIL ADDRESS: STREET 1: 1 BRIDGE PLAZA, SUITE 275 CITY: FORT LEE STATE: NJ ZIP: 07024 D 1 primary_doc.xml X0708 D LIVE 0001875558 Nuvectis Pharma, Inc. 1 BRIDGE PLAZA SUITE 275 FORT LEE NJ NEW JERSEY 07024 (201) 614-3150 DELAWARE Centry Pharma, Inc. None Corporation true 2020 Ron Bentsur C/O Nuvectis Pharma, Inc. 1 Bridge Plaza, Suite 275 Fort Lee NJ NEW JERSEY 07024 Executive Officer Director Matthew Kaplan C/O Nuvectis Pharma, Inc. 1 Bridge Plaza, Suite 275 Fort Lee NJ NEW JERSEY 07024 Director Kenneth Hoberman C/O Nuvectis Pharma, Inc. 1 Bridge Plaza, Suite 275 Fort Lee NJ NEW JERSEY 07024 Director James Oliviero C/O Nuvectis Pharma, Inc. 1 Bridge Plaza, Suite 275 Fort Lee NJ NEW JERSEY 07024 Director Enrique Poradosu C/O Nuvectis Pharma, Inc. 1 Bridge Plaza, Suite 275 Fort Lee NJ NEW JERSEY 07024 Executive Officer Shay Shemesh C/O Nuvectis Pharma, Inc. 1 Bridge Plaza, Suite 275 Fort Lee NJ NEW JERSEY 07024 Executive Officer Michael Carson C/O Nuvectis Pharma, Inc. 1 Bridge Plaza, Suite 275 Fort Lee NJ NEW JERSEY 07024 Executive Officer Biotechnology Decline to Disclose 06b false 2022-07-27 false true true false 0 H.C. Wainwright & Co. 375 None None 430 PARK AVENUE NEW YORK NY NEW YORK 10022 MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK TX TEXAS false 15878637 15878637 0 false 19 1355294 true 0 A cash fee of 7% of aggregate gross proceeds of the private placement, management fee of 1% of of aggregate gross proceeds of the private placement, a non-accountable expense allowance of $85,000. 0 false Nuvectis Pharma, Inc. /s/ Ron Bentsur Ron Bentsur Chairman, CEO and President 2022-08-10